Does diabetes impact therapeutic immunomodulation therapy decisions for kidney transplant recipients? Data from the Folic Acid for Vascular Outcome Reduction in Transplant (FAVORIT) trial

Does diabetes impact therapeutic immunomodulation therapy decisions for kidney transplant recipients? Data from the Folic Acid for Vascular Outcome Reduction in Transplant (FAVORIT) trial

Larry A Weinrauch,1–4 John A D’Elia,2–4 Matthew R Weir,5 Suphamai Bunnapradist,6 Peter Finn,1 Jiankang Liu,1 Brian Claggett,1 Anthony P Monaco3,4 1Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA, 2Kidney and Hypertension Section,Joslin Diabet...

Full description

Bibliographic Details
Main Authors: Weinrauch LA, D'Elia JA, Weir MR, Bunnapradist S, Finn P, Liu J, Claggett B, Monaco AP
Format: Article
Language:English
Published: Dove Medical Press 2017-08-01
Series:International Journal of Nephrology and Renovascular Disease
Subjects:
Diabetes Renal Transplant Immunosuppression Medical Therapy Cardiovascular Events
Online Access:https://www.dovepress.com/does-diabetes-impact-therapeutic-immunomodulation-therapy-decisions-fo-peer-reviewed-article-IJNRD

Internet

https://www.dovepress.com/does-diabetes-impact-therapeutic-immunomodulation-therapy-decisions-fo-peer-reviewed-article-IJNRD

Similar Items